title: [The effect of SonoVue in endocardial border delineation and myocardial perfusion].
abstract: OBJECTIVE
  To evaluate the enhancement of endocardial border delineation and displaying of myocardial perfusion by the contrast agent SonoVue intravenously.
  
  
  METHODS
  Under mode of fundamental imaging and nonlinear imaging respectively, 90 patients were injected with SonoVue and observed for improvement of endocardial border delineation by two dimension echo. In the meantime, displaying of myocardial perfusion by SonoVue was also investigated under mode of nonlinear imaging. Adverse events were monitored.
  
  
  RESULTS
  (1) SonoVue stained the left heart chambers of the patients right away after the right heart chambers had been stained. Endocardial border delineation of the left heart in 90 patients were all improved by SonoVue. (2) SonoVue can well display myocardial opacification (3) No serious adverse events occurred throughout the study. All nonserious adverse events were minor, mild, and rapidly self-resolving. Total incidence of adverse events was 6.8% and the incidence of adverse events possibly related to SonoVue was 1.1%.
  
  
  CONCLUSIONS
  SonoVue is a safe transpulmonary agent and can satisfactorily improve the endocardial border delineation and show myocardial perfusion.
authors.affiliation: Depatment of Cardiology, Peiking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing 100730, China. fanglg@yahoo.com
authors.forename: Li-Gang
authors.initials: LG
authors.lastname: Fang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003287:Contrast Media / Q000009:adverse effects; D003326:Coronary Circulation; D004452:Echocardiography / Q000379:methods*; D004699:Endocardium / Q000000981:diagnostic imaging*; D005260:Female; D006352:Heart Ventricles / Q000000981:diagnostic imaging; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000008:administration & dosage / Q000009:adverse effects; D013459:Sulfur Hexafluoride / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D003287:Contrast Media; D010743:Phospholipids; C420843:contrast agent BR1; D013459:Sulfur Hexafluoride